Nuvalent, Inc. NUVL
We take great care to ensure that the data presented and summarized in this overview for Nuvalent, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NUVL
View all-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.52 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$379 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$313 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$229 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$226 Million7.96% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.7MShares$205 Million49.52% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA1.69MShares$128 Million28.04% of portfolio
-
State Street Corp Boston, MA1.24MShares$94.3 Million0.01% of portfolio
-
Woodline Partners LP San Francisco, CA1.19MShares$90.5 Million1.11% of portfolio
-
Boxer Capital, LLC San Diego, CA1.12MShares$85 Million6.08% of portfolio
Latest Institutional Activity in NUVL
Top Purchases
Top Sells
About NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at NUVL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 15
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-2.54%
|
$2,052,000
$76.1 P/Share
|
|
Jan 15
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+8.91%
|
$729,000
$27.85 P/Share
|
|
Jan 06
2025
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,483
-1.34%
|
$196,157
$79.38 P/Share
|
|
Jan 06
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+23.09%
|
-
|
|
Jan 06
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,016
-2.63%
|
$317,264
$79.38 P/Share
|
|
Jan 06
2025
|
Darlene Noci Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+26.48%
|
-
|
|
Jan 06
2025
|
Christopher Durant Turner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,016
-2.05%
|
$317,264
$79.38 P/Share
|
|
Jan 06
2025
|
Christopher Durant Turner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+21.98%
|
-
|
|
Jan 06
2025
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,964
-1.93%
|
$234,156
$79.38 P/Share
|
|
Jan 06
2025
|
Deborah Ann Miller Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+26.48%
|
-
|
|
Jan 06
2025
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
17,301
-2.21%
|
$1,366,779
$79.38 P/Share
|
|
Jan 06
2025
|
James Richard Porter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
56,250
+17.44%
|
-
|
|
Jan 06
2025
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,016
-2.07%
|
$317,264
$79.38 P/Share
|
|
Jan 06
2025
|
Alexandra Balcom Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+22.19%
|
-
|
|
Dec 23
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.45%
|
$166,000
$83.9 P/Share
|
|
Dec 19
2024
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+9.48%
|
$0
$0.65 P/Share
|
|
Dec 17
2024
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,700
+13.54%
|
$41,100
$3.99 P/Share
|
|
Dec 16
2024
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,414
+11.22%
|
$0
$0.76 P/Share
|
|
Dec 16
2024
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-6.46%
|
$2,322,000
$86.71 P/Share
|
|
Dec 16
2024
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+11.15%
|
$729,000
$27.85 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 194K shares |
|---|---|
| Exercise of conversion of derivative security | 366K shares |
| Open market or private sale | 4.85M shares |
|---|